CreativeOne Wealth LLC Makes New $392,000 Investment in iShares Biotechnology ETF (NASDAQ:IBB)

CreativeOne Wealth LLC purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,696 shares of the financial services provider’s stock, valued at approximately $392,000.

Other institutional investors also recently bought and sold shares of the company. Darwin Wealth Management LLC purchased a new position in iShares Biotechnology ETF during the 3rd quarter worth approximately $29,000. Highline Wealth Partners LLC purchased a new position in iShares Biotechnology ETF during the 3rd quarter worth approximately $30,000. Bbjs Financial Advisors LLC purchased a new position in iShares Biotechnology ETF during the 2nd quarter worth approximately $31,000. Ashton Thomas Securities LLC acquired a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth approximately $36,000. Finally, Voisard Asset Management Group Inc. acquired a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth approximately $59,000. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Down 0.0 %

Shares of NASDAQ IBB opened at $141.55 on Monday. iShares Biotechnology ETF has a 12 month low of $119.95 and a 12 month high of $150.57. The firm’s 50 day simple moving average is $142.71 and its 200-day simple moving average is $142.06.

iShares Biotechnology ETF Dividend Announcement

The company also recently disclosed a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were paid a dividend of $0.2005 per share. The ex-dividend date was Wednesday, September 25th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.